Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting

Inclusion criteria: * Patients with type 2 diabetes mellitus treated with insulin glargine once daily and oral blood glucose lowering medication * Patients with a HbA1c \> 7% * Patients with a FBG within range (4-7 mmol/L) at baseline, based on the mean of 3 FBG values (measured 5x during the run-in phase, with the highest and lowest value excluded) Exclusion criteria: * Patients treated with an insulin other than insulin glargine * Patients with hypersensitivity to insulin glargine, insulin glulisine, biphasic insulin aspart/insulin aspart protamine 30/70 or any of the excipients * Patients with a (pre)proliferative retinopathy (an optic fundus examination should have been performed within the 2 years prior to study entry) * Pregnant or lactating women * Patients who are unable to fill in the PRO (Patient Reported Outcomes) questionnaires The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.